Navigation Links
Midwest life science companies capture 3% of VC investments in Q.2

CHICAGOEarlier this summer, we looked at venture capital funding in the U.S. during the first quarter of 2004, which reached about $5 billion in investments in small companies.

While promising, this level was lower than the $5.4 billion invested during the fourth quarter of 2003, according to PricewaterhouseCooper's ......

Full article >>>
'"/>

Source:wistechnology.com By Michael Rosen 08/16/04


Page: 1 2

Related biology technology :

1. Midwest life science stocks kept sizzling in Q2
2. Midwest life science stocks sizzle in a tepid first quarter
3. A Midwest passage to India, Part II
4. Midwest offers non-stop flight to North Carolina research park
5. A Midwest life-science odyssey comes full circle
6. Midwest hotter for healthcare investments
7. A Midwest small-cap, life-science surprise package
8. 2006: A mixed blessing for Midwest life science companies
9. Midwest gaining stature in nanotech research
10. Midwest colleges strong contenders for NIH funds
11. Japan on the rebound: Implications for Midwest

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Midwest life science companies capture investments

(Date:11/19/2009)..., BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ ...ator in biotechnology for diabetes therapy, and a ...rvices to food, supplement, biotechnology and phar...of Tuesday,s Annual Meeting of Shareholders. ,,...ted (Nasdaq: SPEX ) elected the following members...
(Date:11/19/2009)... World,s Top Gene Synthesis Comp... (IGSC) to Coordinate Best Practices in Risk Reduc... of Worldwide Gene Synthesis Capacity , ...f the world’s leading gene synthesis compani...a common screening protocol to promote biosecurity...
(Date:11/18/2009)...ecurity personnel need to be able to find explosiv...ith them. To aid such searches, the National Insti...ort from the Department of Homeland Security, has ...dard Reference Material (SRM) 2905, Trace Particul...ry assay methods, the SRM will be helpful in calib...
(Date:11/18/2009)..., IRVINE, Calif., Nov. 18 /PRNewswire-FirstCall/...se CO-Oximetry(TM) and Measure-Through Motion and ... Lyon, France-based Uni.H.A., one of the largest h...France, has signed a multi-year purchasing agreeme...imeters. The agreement offers preferred contract ...
Breaking Biology Technology:Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4New NIST trace explosives standard slated for homeland security duty 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 4
...e-FirstCall/ - Oncothyreon Inc. (NASDAQ:,ONTY) (TS...zation plan to,focus the Company,s resources on th... process development and manufacturing of Stimuvax...linical development of PX-12,beyond the ongoing tr...ntrate Oncothyreon,s efforts and available resourc...
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced t...nt in a Phase 1 trial of CVT-3619, a novel oral co...diseases. The U.S. Food and Drug,Administration re...drug,application for CVT-3619, a partial A1 adenos...sess the safety and pharmacokinetic profile,of CVT...
...alidity of Purdue patents; Purdue licenses ...hs, STAMFORD, Conn., Sept. 2 Purdue Pharma L.P. ...Hazelwood, Missouri have,agreed to end the OxyCont...atent infringement lawsuit between them in the Uni...t of New York., According to the agreement, Malli...
Other Biology Technology:Oncothyreon announces prioritization plan for development programs 2Oncothyreon announces prioritization plan for development programs 3Oncothyreon announces prioritization plan for development programs 4Oncothyreon announces prioritization plan for development programs 5CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 2CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 3Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc. 2
(Date:11/20/2009)...s are at work on many scientific and technological...cently provided support that totals nearly $4.3 mi...estigators under the American Recovery and Reinves...n awarded grants for investigation of solar phenom...hysics, will enhance the capabilities of NJIT,s Bi...
(Date:11/20/2009)...nvited to contribute their abstracts to the World ...the largest global meeting devoted to all aspects ...tient care. The Congress will be held in Florence,...stracts can be submitted online at http://www.iof...ebruary 4, 2010. , IOF and ESCEO are pleased to ...
(Date:11/20/2009)...tion of a single bacterial gene into yeast, resear...etherlands achieved three improvements in bioethan...ore ethanol, less acetate and elimination of the m...was published in the scientific journal Applied a... Bioethanol is made by the yeast Saccharomyces cer...
Breaking Biology News(10 mins):NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3Delft breakthrough in bioethanol production from agricultural waste 2Image Sensors 2009 Announces Final Program and New Interactive Brochure 52852 1Image Sensors 2009 Announces Final Program and New Interactive Brochure 52852 2Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 1Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 2Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 3Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 4Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 5Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 6Many Heart Attack Patients Not Referred to Cardiac Rehab 52843 1Many Heart Attack Patients Not Referred to Cardiac Rehab 52843 2Many Heart Attack Patients Not Referred to Cardiac Rehab 52843 3
...ein secreted by mussels and a polymer that repels ...iversity have designed a versatile new two-sided c...ts. , Currently the longevity of certain medical ...ins in the body gradually accumulate on the device...ce and threatening patients with infections. Unfor...
...adly form of skin cancer very resistant to treatme...mp; Research Institute and the University of South...prompts the immune system to aid in the fight agai...al trial because it is the first time that electro... gene therapy study in humans," said Richard Helle...
...from Columbia University Medical Center have shown...bris from blocked arteries during a heart attack d..., called distal microcirculatory protection, is co... vein grafts and stenting in carotid arteries. The...nal of the American Medical Association, found tha...
Other Biology News:Innovative coating could give medical implants a longer life 2Researchers test new therapy for advanced melanoma 2Columbia study shows widely used artery clearing device does not help patients during heart attack 2
Caveolin Sampler Kit from BD Biosciences Pharmingen
UCB Eosinophil Chip-IHC from 3H Biomedical AB
UCB MSC Cell Chip-IHC from 3H Biomedical AB
B Cell Chip-IHC from 3H Biomedical AB
Biology Products: